BR112022008552A2 - Moléculas de ligação multiespecíficas de scfv de terminal-n - Google Patents

Moléculas de ligação multiespecíficas de scfv de terminal-n

Info

Publication number
BR112022008552A2
BR112022008552A2 BR112022008552A BR112022008552A BR112022008552A2 BR 112022008552 A2 BR112022008552 A2 BR 112022008552A2 BR 112022008552 A BR112022008552 A BR 112022008552A BR 112022008552 A BR112022008552 A BR 112022008552A BR 112022008552 A2 BR112022008552 A2 BR 112022008552A2
Authority
BR
Brazil
Prior art keywords
mbms
binding molecules
specific binding
terminal scfv
conjugates
Prior art date
Application number
BR112022008552A
Other languages
English (en)
Portuguese (pt)
Inventor
Shen Yang
Lee Ann-Hwee
Yang Yan
Lin Chia-Yang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112022008552A2 publication Critical patent/BR112022008552A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022008552A 2019-11-05 2020-11-04 Moléculas de ligação multiespecíficas de scfv de terminal-n BR112022008552A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930916P 2019-11-05 2019-11-05
PCT/US2020/058798 WO2021091953A1 (en) 2019-11-05 2020-11-04 N-terminal scfv multispecific binding molecules

Publications (1)

Publication Number Publication Date
BR112022008552A2 true BR112022008552A2 (pt) 2022-08-09

Family

ID=73598993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008552A BR112022008552A2 (pt) 2019-11-05 2020-11-04 Moléculas de ligação multiespecíficas de scfv de terminal-n

Country Status (12)

Country Link
US (3) US12240907B2 (https=)
EP (1) EP4054646A1 (https=)
JP (2) JP7785669B2 (https=)
KR (1) KR20220093363A (https=)
CN (1) CN114786730A (https=)
AU (1) AU2020379735A1 (https=)
BR (1) BR112022008552A2 (https=)
CA (1) CA3157075A1 (https=)
IL (1) IL292698A (https=)
MX (1) MX2022005330A (https=)
TW (1) TW202134277A (https=)
WO (1) WO2021091953A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005330A (es) * 2019-11-05 2022-05-26 Regeneron Pharma Moleculas de union multiespecificas con scfv en el extremo nterminal.
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
CN114716548B (zh) * 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
CA3219609A1 (en) * 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
KR20250148746A (ko) * 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
WO2025088587A1 (en) * 2023-10-27 2025-05-01 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2025240335A1 (en) * 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
MA33208B1 (fr) * 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
AU2010254013A1 (en) 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9337942B2 (en) 2009-12-07 2016-05-10 Ntt Docomo, Inc. Propagation path estimation method and program and apparatus using the same
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA030462B1 (ru) * 2011-05-16 2018-08-31 Дженентек, Инк. Агонисты fgfr1 и способы их применения
UY34542A (es) 2011-12-23 2013-07-31 Mersana Therapeutics Inc ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
EP3107565A4 (en) 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
AU2015236073B2 (en) * 2014-03-25 2020-04-30 Regeneron Pharmaceuticals, Inc. FGF21 receptor agonists and uses thereof
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
US10526404B2 (en) 2015-04-29 2020-01-07 Institute For Research In Biomedicine Multispecific anti GM-CSF antibodies
IL296285A (en) * 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
KR20260018979A (ko) 2016-02-05 2026-02-09 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019005552A (es) 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
DK3635009T3 (da) * 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
US20200157224A1 (en) 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
KR102871690B1 (ko) * 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
MX2022005330A (es) 2019-11-05 2022-05-26 Regeneron Pharma Moleculas de union multiespecificas con scfv en el extremo nterminal.

Also Published As

Publication number Publication date
AU2020379735A1 (en) 2022-05-26
JP2026016376A (ja) 2026-02-03
EP4054646A1 (en) 2022-09-14
US20210130477A1 (en) 2021-05-06
MX2022005330A (es) 2022-05-26
JP2022553830A (ja) 2022-12-26
JP7785669B2 (ja) 2025-12-15
US12240908B2 (en) 2025-03-04
TW202134277A (zh) 2021-09-16
US20220251220A1 (en) 2022-08-11
KR20220093363A (ko) 2022-07-05
IL292698A (en) 2022-07-01
US20250171545A1 (en) 2025-05-29
WO2021091953A1 (en) 2021-05-14
CN114786730A (zh) 2022-07-22
US12240907B2 (en) 2025-03-04
CA3157075A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112022008552A2 (pt) Moléculas de ligação multiespecíficas de scfv de terminal-n
WO2020010250A3 (en) Anti-tcr antibody molecules and uses thereof
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
MX2019001469A (es) Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
WO2021138474A3 (en) Anti-tcr antibody molecules and uses thereof
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
WO2020172596A8 (en) Anti-tcr antibody molecules and uses thereof
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
EP4219559A3 (en) Antibodies for lilrb2
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
MX2016014000A (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
BR112022002067A2 (pt) Formatos de molécula de ligação ao antígeno
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022024691A2 (pt) Conjugados anticorpo biespecífico - fármaco direcionados a egfr e muc1 e usos dos mesmos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]